“Find me a doctor. Not just any doctor, but a good Jewish doctor!… who can cure cancer” 😀
Bold claim (yeah we’ll cure that as well!)
An Israeli pharmaceutical company is claiming it will have a “complete cure for cancer” within the next year.
The company is Accelerated Evolution Biotechnologies (AEBi), and based on the claims of its board chairman Dan Aridor, the treatment it’s working on sounds nothing short of revolutionary.
“Our cancer cure will be effective from day one, will last a duration of a few weeks, and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor told The Jerusalem Post. “Our solution will be both generic and personal.”
According to The Jerusalem Post, AEBi’s cancer cure is called MuTaTo, which stands for “multi-target toxin.” It attacks cancer cells with several peptides — compounds comprising chains of amino acids — at once, and this multi-pronged attack is key to the treatment’s efficacy, the company says.
“We made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer,” AEBi CEO Ilan Morad told the Post. “The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used.”
“Instead of attacking receptors one at a time, we attack receptors three at a time,” he continued. “Not even cancer can mutate three receptors at the same time.”
State of the Cure
Morad claims in the Post that AEBi has used its cancer treatment to inhibit human cancer cell growth in mice without affecting the animals’ healthy cells at all. The company has also completed several in-vitro trials and will soon begin clinical trials, according to Morad. Those could wrap up within a few years, said AEBi’s CEO, after which the treatment could be available in specific cases.
That’s a lot of claims, but the Post article doesn’t mention the existence of any peer-reviewed research that could back them up.
Clearly, the kind of treatment AEBi is proposing would be extraordinary — after all, cancer is the second most common cause of death across the globe. But we’ll reserve our excitement until after this pharmaceutical company’s cancer cure stands up to the scrutiny of the scientific community.
Brian Wang | January 28, 2019
Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say the AEBi anti-cancer treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order. They are using peptides.
MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically. By using at least three targeting peptides on the same structure with a strong toxin, AEBi made sure that the treatment will not be affected by mutations. Cancer cells can mutate in such a way that targeted receptors are dropped by the cancer.
Some cancer tumors erect shields which create access problems to large molecules, such as antibodies. MuTaTo acts like an octopus or a piece of spaghetti and can sneak into places where other large molecules cannot reach. Morad said the peptide parts of MuTaTo are very small (12 amino acids long) and lack a rigid structure.
AEBi finished its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials. AEBi will soon begin a round of clinical trials which could be completed within a few years and would make the treatment available in specific cases.
Solution Benefit Summary
* The solution will hit and activate or deactivate any protein-based target.
* They dramatically expand the range of targets, to include even the most challenging ones.
* They are able to optimize. They have an unparalleled high “signal to noise” ratio.
AEBi Platform features:
* No limit on the number of rounds in the screening process.
* Each round has both affinity and efficacy properties.
* Hitting the hardest targets.
AEBi (Accelerated Evolution Biotechnologies) is a development-stage biopharmaceutical company engaged in discovery and development of therapeutic peptides. They developed a combinatorial biology screening platform technology which they call the SoAP platform. It provides functional leads to very difficult targets.
The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. They introduce DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. The protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.
In 2018, a team of scientists won the Nobel Prize for their work on phage display in the directed evolution of new proteins – in particular, for the production of antibody therapeutics.
AEBi is doing something similar but with peptides, compounds of two or more amino acids linked in a chain. According to Morad, peptides have several advantages over antibodies, including that they are smaller, cheaper, and easier to produce and regulate.
Written by Brian Wang, Nextbigfuture.com
The Great MuTaTo!
WHAT FILM IS THAT OFF!
It’s an X Files Episode! 😀